Kyaw Lwin Aung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kyaw Lwin Aung has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Shrawat
College of Natural Sciences, The University of Texas at Austin, Austin, Texas
27 shared publications - Akshay Bhat
Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas
27 shared publications - Alessia Lodi
Department of Nutritional Sciences, College of Natural Sciences and Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
27 shared publications - Ashok Singh
Dell Medical School, The University of Texas at Austin, Austin, Texas
27 shared publications - Dan Qi
Department of Neurosurgery and Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76508, USA
27 shared publications - Daniel J. McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
27 shared publications
Latest Publications
- 12 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Global Authorship Patterns in Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025
Purpose: Authorship of phase III oncology trials reflects broader patterns of scientific leadership, including access to resources, research infrastructure, and global participation. However, how these factors intersect with gender over time remains incompletely characterized. We evaluated trends in authorship across phase III solid-tumor trials presented at the ASCO Annual Meeting from 2015 to 2025. Methods: We conducted a repeated cross-sectional study of phase III solid-tumor abstracts presented at ASCO (2015-2025). Author gender was assigned using a multistep approach based on publicly available data. Outcomes included authorship by role (first v senior), tumor track, funding source, trial-origin geographic region, and trial-origin World Bank income group. Multivariable logistic regression identified factors associated with female authorship. Results: Among 1,517 abstracts (3,034 authorships), 27.9% of authors were women. Female authorship increased from 24.9% in 2015-2020 to 30.0% in 2021-2025 ( P = .002). Women were more likely to be first than senior authors (54.7% v 45.3%, P = .002) and were less likely to hold senior authorship overall (adjusted odds ratio [OR], 0.76, 95% CI 0.65-0.90; P = .001). Temporal gains were driven by increased female senior authorship (OR, 1.55 [95% CI, 1.20 to 1.99]; P = .001). Female authorship was lower in several tumor types and in East Asia and Pacific versus North America (OR, 0.65 [95% CI, 0.48 to 0.87]; P = .003). Funding and income group were not associated with female authorship. Conclusion: Women remain underrepresented in phase III oncology trial authorship, particularly in senior roles and across certain tumor types and regions, suggesting persistent gaps in authorship representation that may reflect broader structural barriers.
- 12 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Global Authorship Patterns in Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025
Purpose: Authorship of phase III oncology trials reflects broader patterns of scientific leadership, including access to resources, research infrastructure, and global participation. However, how these factors intersect with gender over time remains incompletely characterized. We evaluated trends in authorship across phase III solid-tumor trials presented at the ASCO Annual Meeting from 2015 to 2025. Methods: We conducted a repeated cross-sectional study of phase III solid-tumor abstracts presented at ASCO (2015-2025). Author gender was assigned using a multistep approach based on publicly available data. Outcomes included authorship by role (first v senior), tumor track, funding source, trial-origin geographic region, and trial-origin World Bank income group. Multivariable logistic regression identified factors associated with female authorship. Results: Among 1,517 abstracts (3,034 authorships), 27.9% of authors were women. Female authorship increased from 24.9% in 2015-2020 to 30.0% in 2021-2025 ( P = .002). Women were more likely to be first than senior authors (54.7% v 45.3%, P = .002) and were less likely to hold senior authorship overall (adjusted odds ratio [OR], 0.76, 95% CI 0.65-0.90; P = .001). Temporal gains were driven by increased female senior authorship (OR, 1.55 [95% CI, 1.20 to 1.99]; P = .001). Female authorship was lower in several tumor types and in East Asia and Pacific versus North America (OR, 0.65 [95% CI, 0.48 to 0.87]; P = .003). Funding and income group were not associated with female authorship. Conclusion: Women remain underrepresented in phase III oncology trial authorship, particularly in senior roles and across certain tumor types and regions, suggesting persistent gaps in authorship representation that may reflect broader structural barriers.
- Open Access
- 2 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management
Cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and muscle wasting, affecting over 80% of patients with pancreatic cancer. It decreases treatment tolerance, quality of life, and survival. Yet, despite its well-recognized detrimental impact, cachexia remains underdiagnosed and undertreated in oncology clinics. This review synthesizes current understanding of pancreatic cancer cachexia with an emphasis on its complex pathophysiology involving inflammatory cytokines, tumor-derived catabolic factors, neuroendocrine disruption, and pancreatic insufficiency as advancing insight into these underlying mechanisms is driving the development of targeted therapies for cachexia. A narrative review of the literature was performed using PubMed, Embase, and Google Scholar to identify studies related to pancreatic cancer cachexia. Relevant peer-reviewed clinical trials, translational studies, and review articles focusing on pathophysiology, nutritional assessment, and management strategies were prioritized. Emerging therapeutic strategies targeting the underlying biology of cachexia, including growth differentiation factor-15 inhibition, inflammatory pathway blockade, and ghrelin receptor agonism, have demonstrated encouraging effects on weight, muscle preservation, appetite, and functional measures. Advances in nutritional assessment, body composition analysis, and biomarker development may further improve early detection and management. Pancreatic cancer cachexia should be recognized as an active and potentially modifiable process rather than an inevitable consequence of advanced disease. Earlier identification, multidisciplinary management, and emerging mechanism-based therapies may improve clinical outcomes and quality of life for patients with pancreatic cancer.
- 2 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Open AccessPancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management
Cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and muscle wasting, affecting over 80% of patients with pancreatic cancer. It decreases treatment tolerance, quality of life, and survival. Yet, despite its well-recognized detrimental impact, cachexia remains underdiagnosed and undertreated in oncology clinics. This review synthesizes current understanding of pancreatic cancer cachexia with an emphasis on its complex pathophysiology involving inflammatory cytokines, tumor-derived catabolic factors, neuroendocrine disruption, and pancreatic insufficiency as advancing insight into these underlying mechanisms is driving the development of targeted therapies for cachexia. A narrative review of the literature was performed using PubMed, Embase, and Google Scholar to identify studies related to pancreatic cancer cachexia. Relevant peer-reviewed clinical trials, translational studies, and review articles focusing on pathophysiology, nutritional assessment, and management strategies were prioritized. Emerging therapeutic strategies targeting the underlying biology of cachexia, including growth differentiation factor-15 inhibition, inflammatory pathway blockade, and ghrelin receptor agonism, have demonstrated encouraging effects on weight, muscle preservation, appetite, and functional measures. Advances in nutritional assessment, body composition analysis, and biomarker development may further improve early detection and management. Pancreatic cancer cachexia should be recognized as an active and potentially modifiable process rather than an inevitable consequence of advanced disease. Earlier identification, multidisciplinary management, and emerging mechanism-based therapies may improve clinical outcomes and quality of life for patients with pancreatic cancer.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
Supplementary Figures and Supplementary Table S1
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
Supplementary Figures and Supplementary Table S1
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer